These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22302249)

  • 1. Medication guides leave their REMS programs behind.
    Traynor K
    Am J Health Syst Pharm; 2012 Feb; 69(4):272-3. PubMed ID: 22302249
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shared REMS programs expanded in 2012.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(4):298, 303. PubMed ID: 23370134
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New botulinum toxin approved with REMS.
    Thompson CA
    Am J Health Syst Pharm; 2010 Sep; 67(18):1486. PubMed ID: 20811019
    [No Abstract]   [Full Text] [Related]  

  • 6. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?
    Cohen RA; Brown RS
    Am J Kidney Dis; 2012 May; 59(5):604-6. PubMed ID: 22361042
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 10. Stakeholders say FDA must change REMS program.
    Reinke T
    Manag Care; 2011 Mar; 20(3):8-9. PubMed ID: 21485624
    [No Abstract]   [Full Text] [Related]  

  • 11. Warning signs.
    Nature; 2008 Mar; 452(7185):254. PubMed ID: 18354433
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA perspective on risk management programs.
    Woodcock J
    J Am Pharm Assoc (Wash); 2001; 41(6 Suppl 1):S16-7. PubMed ID: 11764272
    [No Abstract]   [Full Text] [Related]  

  • 13. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
    Childs L; Alexander E; Duong MT
    Am J Health Syst Pharm; 2012 May; 69(10):885-9. PubMed ID: 22555085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Dear Healthcare Professional' letters may not be effective REMS communication tool.
    Thompson CA
    Am J Health Syst Pharm; 2014 Feb; 71(3):177-8. PubMed ID: 24429006
    [No Abstract]   [Full Text] [Related]  

  • 16. With REMS, what goes up can come down.
    Thompson CA
    Am J Health Syst Pharm; 2011 May; 68(9):783-4. PubMed ID: 21515857
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.